PT1585513E - Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia - Google Patents

Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia

Info

Publication number
PT1585513E
PT1585513E PT03812244T PT03812244T PT1585513E PT 1585513 E PT1585513 E PT 1585513E PT 03812244 T PT03812244 T PT 03812244T PT 03812244 T PT03812244 T PT 03812244T PT 1585513 E PT1585513 E PT 1585513E
Authority
PT
Portugal
Prior art keywords
treatment
active substance
lipodistrofia
docosa
hexaenoic acid
Prior art date
Application number
PT03812244T
Other languages
English (en)
Inventor
Domingo Pedrol Pere
Domingo Pedrol Juan Carlos
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Publication of PT1585513E publication Critical patent/PT1585513E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
PT03812244T 2002-12-05 2003-12-01 Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia PT1585513E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.

Publications (1)

Publication Number Publication Date
PT1585513E true PT1585513E (pt) 2006-10-31

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03812244T PT1585513E (pt) 2002-12-05 2003-12-01 Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia

Country Status (24)

Country Link
US (1) US8202906B2 (pt)
EP (1) EP1585513B1 (pt)
JP (1) JP2006511514A (pt)
KR (1) KR100906086B1 (pt)
CN (1) CN100355421C (pt)
AT (1) ATE326959T1 (pt)
AU (1) AU2003302679B2 (pt)
BR (1) BR0316973A (pt)
CA (1) CA2506993C (pt)
CY (1) CY1105205T1 (pt)
DE (1) DE60305534T2 (pt)
DK (1) DK1585513T3 (pt)
EA (1) EA009711B1 (pt)
ES (2) ES2209658B1 (pt)
IL (1) IL168766A (pt)
IS (1) IS2384B (pt)
MX (1) MXPA05005911A (pt)
NO (1) NO20052960L (pt)
NZ (1) NZ540262A (pt)
PL (1) PL377563A1 (pt)
PT (1) PT1585513E (pt)
UA (1) UA79650C2 (pt)
WO (1) WO2004050077A1 (pt)
ZA (1) ZA200503872B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
DK2234620T3 (en) 2008-01-03 2016-06-06 Université D'aix-Marseille Triple therapy used for treatment of an hiv-infected patient
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
EP1121928B1 (en) * 2000-01-31 2008-01-23 Härting S.A. Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
ATE305810T1 (de) * 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
IS2384B (is) 2008-07-15
ES2265607T3 (es) 2007-02-16
EP1585513A1 (en) 2005-10-19
ES2209658A1 (es) 2004-06-16
AU2003302679B2 (en) 2009-01-15
BR0316973A (pt) 2005-10-25
PL377563A1 (pl) 2006-02-06
ATE326959T1 (de) 2006-06-15
IL168766A (en) 2009-11-18
DE60305534D1 (de) 2006-06-29
UA79650C2 (en) 2007-07-10
CN100355421C (zh) 2007-12-19
DE60305534T2 (de) 2007-05-16
WO2004050077A1 (en) 2004-06-17
EA009711B1 (ru) 2008-02-28
MXPA05005911A (es) 2005-08-29
AU2003302679A1 (en) 2004-06-23
KR20050085313A (ko) 2005-08-29
EA200500765A1 (ru) 2005-12-29
CA2506993C (en) 2010-04-13
CA2506993A1 (en) 2004-06-17
NO20052960L (no) 2005-06-16
JP2006511514A (ja) 2006-04-06
EP1585513B1 (en) 2006-05-24
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
DK1585513T3 (da) 2006-09-18
ZA200503872B (en) 2006-08-30
CN1720039A (zh) 2006-01-11
US20060178436A1 (en) 2006-08-10
US8202906B2 (en) 2012-06-19
NZ540262A (en) 2006-11-30
KR100906086B1 (ko) 2009-07-06
CY1105205T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
MY147864A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
IS2384B (is) Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking
EA201270615A1 (ru) Противогрибковый препарат, содержащий грибковый организм
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
BRPI0418157A (pt) terapêutica de tumores alogênicos
CL2018003346A1 (es) Uso de hidrolizado de colágeno para preparar un medicamento contra la pérdida degenerativa de masa muscular (sarcopenia) y para mejorar la fuerza muscular (divisional de solicitud 3326-2015).
DK1343472T3 (da) Thixotropisk næsespray
RU2423118C1 (ru) Способ лечения трофических язв
US20150086529A1 (en) Therapeutic Burn Gel
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
Raffaele et al. Treatment of Low Level Laser Therapy in the Oral Manifestations of Steven Johnson Syndrome
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
Castillo et al. Reply to:“Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need”
Foell Acupuncture as add-on treatment in the management of a patient with ecthyma gangrenosum
KR20150066698A (ko) 치료용 엘이디 밴드
CN103142676A (zh) 一种接骨化瘀生肌丸
FR2884423A1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
RU2195947C2 (ru) Способ лечения остеохондропатий
Kumari et al. ROLE OF PRIYANGVADI TAILA IN THE MANAGEMENT OF DIABETIC WOUND-A CASE REPORT
Karakolevska Ilova et al. Kancerska bolka
Storan Calcium/colecalciferol
CN105497269A (zh) 一种治疗白癜风的外用药
Camera Fall head over heels in love--with your feet